Pulmonology Center of Excellence

Supporting patients living with a rare pulmonology condition

Orsini’s Pulmonology Center of Excellence launched in 2014 with our first program for idiopathic pulmonary fibrosis (IPF). Today we support multiple pulmonology programs across several rare conditions. Our dedicated Therapy Care Teams work with the physician’s office and insurance on a patient’s behalf so that our patients and their family have more time to focus on their treatment and quality of life. We are here to listen, provide counseling on treatment, including side-effect management, and assist with sourcing third-party financial assistance.

Explore Our Pulmonology Therapies

Benefits

Improving the Patient Experience, Every Time

Dedicated Care Team

Receive personalized support from a dedicated Therapy Care Team, including a primary pharmacy contact, clinical education, side-effects management, and scheduled refill calls.

Patient-Centered Care

Experience compassionate care that prioritizes patients and their families. Our team supports patients of all ages, from infants to the elderly, extending care to the entire care team.

Insurance Coverage

Secure treatment coverage with assistance navigating payor and plan requirements. Our team proactively works with prescribers to obtain prior authorization and support appeals.

Free Care Overnight Shipping

Ensure medication and essential medical supplies arrive when and where patients need them through coordination across prescribers, patients, and care teams to arrange free overnight shipping.

Financial Assistance

Minimize financial exposure through financial assistance programs. We successfully identify and assist in enrolling patients into manufacturer co-pay and foundation support programs.

24/7/365 Access to a Pharmacist

Gain continuous access to a pharmacist, 24/7/365, ensuring ongoing care and clinical support for patients and prescribers to achieve better outcomes.

Support

Pulmonology Conditions Supported

Explore the rare pulmonology conditions and therapies Orsini supports below.

About Chronic Fibrosing Interstitial Lung Diseases (ILDs)

Chronic fibrosing interstitial lung diseases are a group of conditions in which a patient’s lung tissue becomes scarred and thickened over time. This scarring—known as fibrosis—makes the lungs stiff and less able to expand, which interferes with oxygen moving into the bloodstream, and can gradually worsen over time. Those living with chronic fibrosing ILDs often experience, among other symptoms, shortness of breath, a persistent dry cough, exercise intolerance, unintentional weight loss, and and early mortality.

Chronic Fibrosing ILD Therapies Supported

Nintedanib Featured Image_Orsini Website

Full Name	nintedanib
Drug	nintedanib
Manufacturer	Generic
Route of Administration	Oral
Site of Care	Home
Approved Indication	Indicated in adults for: • Treatment of idiopathic pulmonary fibrosis (IPF) • Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype
Disease	Idiopathic Pulmonary Fibrosis (IPF); Chronic Fibrosing Interstitial Lung Diseases (ILDs)
Therapeutic Area	Pulmonology
Enrollment Form Link	Enrollment Form
Phone Number	800-373-1452
Fax Number	888-975-1456
Patient Resources	Pulmonary Fibrosis Foundation On-Demand Webinar: Breathing Easier: What to Know about Pulmonary Fibrosis — and How Pulmonary Rehab Can Help

Boehringer Ingelheim -Canada- Ltd--OFEV- -nintedanib- receives p

Full Name	Ofev® (nintedanib)
Drug	Ofev
Manufacturer	Boehringer Ingelheim
Route of Administration	Oral
Site of Care	Home
Approved Indication	Treatment of idiopathic pulmonary fibrosis (IPF) in adults, treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype in adults, or slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Disease	Idiopathic Pulmonary Fibrosis (IPF); Chronic Fibrosing Interstitial Lung Diseases (ILDs); Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)
Therapeutic Area	Pulmonology
Enrollment Form Link	Enrollment Form
Phone Number	800-373-1452
Fax Number	888-975-1456
Product Website	ofev.com
Patient Resources	Pulmonary Fibrosis Foundation On-Demand Webinar: Breathing Easier: What to Know about Pulmonary Fibrosis — and How Pulmonary Rehab Can Help

About Idiopathic Pulmonary Fibrosis (IPF)

Idiopathic pulmonary fibrosis is a progressive lung disease characterized by the gradual thickening and scarring of lung tissue. This scarring hinders the lungs’ ability to efficiently transfer oxygen into the bloodstream, resulting in debilitating symptoms. Individuals with IPF often experience shortness of breath, a persistent dry cough, fatigue, unexplained weight loss, and muscle and joint aches. The term ‘idiopathic’ indicates an unknown cause, adding to the complexity of the condition.

IPF Therapies Supported

Full Name	Esbriet® (pirfenidone)
Drug	Esbriet
Manufacturer	Genentech
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of idiopathic pulmonary fibrosis (IPF)
Disease	Idiopathic Pulmonary Fibrosis (IPF)
Therapeutic Area	Pulmonology
Enrollment Form Link	Enrollment Form
Phone Number	800-355-9366
Fax Number	877-358-9246
Product Website	esbriethcp.com
Patient Resources	Pulmonary Fibrosis Foundation On-Demand Webinar: Breathing Easier: What to Know about Pulmonary Fibrosis — and How Pulmonary Rehab Can Help

Full Name	JASCAYD® (nerandomilast)
Drug	nerandomilast
Manufacturer	Boehringer Ingelheim
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of idiopathic pulmonary fibrosis in adult patients The treatment of progressive pulmonary fibrosis in adult patients
Disease	Idiopathic pulmonary fibrosis (IPF); Progressive pulmonary fibrosis (PPF)
Therapeutic Area	Pulmonology
Enrollment Form Link	Enrollment Form
Phone Number	847-239-5646
Fax Number	847-423-6217
Product Website	jascayd.com
Patient Resources	Pulmonary Fibrosis Foundation On-Demand Webinar: Breathing Easier: What to Know about Pulmonary Fibrosis — and How Pulmonary Rehab Can Help

Full Name	nintedanib
Drug	nintedanib
Manufacturer	Generic
Route of Administration	Oral
Site of Care	Home
Approved Indication	Indicated in adults for: • Treatment of idiopathic pulmonary fibrosis (IPF) • Treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype
Disease	Idiopathic Pulmonary Fibrosis (IPF); Chronic Fibrosing Interstitial Lung Diseases (ILDs)
Therapeutic Area	Pulmonology
Enrollment Form Link	Enrollment Form
Phone Number	800-373-1452
Fax Number	888-975-1456
Patient Resources	Pulmonary Fibrosis Foundation On-Demand Webinar: Breathing Easier: What to Know about Pulmonary Fibrosis — and How Pulmonary Rehab Can Help

Full Name	Ofev® (nintedanib)
Drug	Ofev
Manufacturer	Boehringer Ingelheim
Route of Administration	Oral
Site of Care	Home
Approved Indication	Treatment of idiopathic pulmonary fibrosis (IPF) in adults, treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype in adults, or slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Disease	Idiopathic Pulmonary Fibrosis (IPF); Chronic Fibrosing Interstitial Lung Diseases (ILDs); Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)
Therapeutic Area	Pulmonology
Enrollment Form Link	Enrollment Form
Phone Number	800-373-1452
Fax Number	888-975-1456
Product Website	ofev.com
Patient Resources	Pulmonary Fibrosis Foundation On-Demand Webinar: Breathing Easier: What to Know about Pulmonary Fibrosis — and How Pulmonary Rehab Can Help

Full Name	pirfenidone
Drug	Pirfenidone
Manufacturer	Generic
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of idiopathic pulmonary fibrosis (IPF)
Disease	Idiopathic Pulmonary Fibrosis (IPF)
Therapeutic Area	Pulmonology
Enrollment Form Link	Enrollment Form
Phone Number	800-355-9366
Fax Number	877-358-9246
Patient Resources	Pulmonary Fibrosis Foundation On-Demand Webinar: Breathing Easier: What to Know about Pulmonary Fibrosis — and How Pulmonary Rehab Can Help

About Progressive Pulmonary Fibrosis (PPF)

Progressive pulmonary fibrosis is a form of interstitial lung disease in which scarring of the lung tissue not only occurs, but worsens over time, leading to irreversible decline in respiratory function. PPF describes a progressive pattern seen in fibrosing ILDs such as connective tissue disease-associated ILD, chronic hypersensitivity pneumonitis, and occupational lung diseases. Individuals with IPF often experience increasing breathlessness, persistent dry cough, fatigue, and reduced exercise tolerance.

PPF Therapies Supported

Full Name	JASCAYD® (nerandomilast)
Drug	nerandomilast
Manufacturer	Boehringer Ingelheim
Route of Administration	Oral
Site of Care	Home
Approved Indication	The treatment of idiopathic pulmonary fibrosis in adult patients The treatment of progressive pulmonary fibrosis in adult patients
Disease	Idiopathic pulmonary fibrosis (IPF); Progressive pulmonary fibrosis (PPF)
Therapeutic Area	Pulmonology
Enrollment Form Link	Enrollment Form
Phone Number	847-239-5646
Fax Number	847-423-6217
Product Website	jascayd.com
Patient Resources	Pulmonary Fibrosis Foundation On-Demand Webinar: Breathing Easier: What to Know about Pulmonary Fibrosis — and How Pulmonary Rehab Can Help

About Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)

Systemic sclerosis interstitial lung disease is a complex and progressive condition that arises as a complication of systemic sclerosis, an autoimmune disorder. This disease manifests as fibrosis and inflammation in the lungs, impairing their normal function. Common symptoms include breathlessness, persistent cough, and diminished lung capacity. Understanding this interplay between the body’s autoimmune response and lung damage helps in navigating the journey of living with SSc-ILD.

SSc-ILD Therapies Supported

Full Name	Ofev® (nintedanib)
Drug	Ofev
Manufacturer	Boehringer Ingelheim
Route of Administration	Oral
Site of Care	Home
Approved Indication	Treatment of idiopathic pulmonary fibrosis (IPF) in adults, treatment of chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype in adults, or slowing the rate of decline in pulmonary function in adults with systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Disease	Idiopathic Pulmonary Fibrosis (IPF); Chronic Fibrosing Interstitial Lung Diseases (ILDs); Systemic Sclerosis Interstitial Lung Disease (SSc-ILD)
Therapeutic Area	Pulmonology
Enrollment Form Link	Enrollment Form
Phone Number	800-373-1452
Fax Number	888-975-1456
Product Website	ofev.com
Patient Resources	Pulmonary Fibrosis Foundation On-Demand Webinar: Breathing Easier: What to Know about Pulmonary Fibrosis — and How Pulmonary Rehab Can Help

Patient Advocacy Partners

The Alex Rezcalla Foundation advances the development of therapies for individuals with Duchenne muscular dystrophy (DMD) through advocacy and research funding. It raises awareness of the DMD experience by hosting events, engaging the public, and building networks of support.

Learn more at alexrezkallafoundation.org

The Amyloidosis Research improves the lives of patients with amyloidosis and accelerates cutting edge research through collaborative, groundbreaking initiatives. ARC provides support, information, and resources to patients and caregivers, empowering them to access the best care possible.

Learn more at aci.org

Cure SMA is dedicated to finding treatments and a cure for spinal muscular atrophy (SMA) by funding research and supporting families. Since 1984, Cure SMA has grown to be the largest U.S.-based network of individuals, families, clinicians, and research scientists working together to advance SMA research, support individuals and families impacted by SMA, and educate public and professional communities about SMA.

Learn more at www.curesma.org

The US Hereditary Angioedema Association (HAEA) is a 501 (c)(3) non-profit advocacy and research organization serving people living with the rare genetic condition, Hereditary Angioedema (HAE), and their families. Founded and staffed by people with HAE and caregivers, the US HAEA is committed to actively engaging our community in a wide variety of grassroots activities that promote HAE education and awareness.

Learn more at haea.org

The HypoPARAthyroidism Association is a non-profit patient association working to improve the lives of people impacted by hypoPARAthyroidism through education, support, research, and advocacy. They raise awareness of hypoPARAthyroidism and bring change to the lives of those affected.

Learn more at hypopara.org

Jett Foundation empowers people and families impacted by Duchenne muscular dystrophy through the development of transformative programming, educational opportunities, and ongoing support for every stage of a Duchenne journey.

Learn more at jettfoundation.org

Muscular Dystrophy Association (MDA) is the #1 voluntary health organization in the United States for people living with muscular dystrophy, ALS, and over 300 other neuromuscular conditions. For 75 years, MDA has led the way in accelerating research, advancing care, and advocating support and inclusion of families living with neuromuscular disease.

Learn more at mda.org

The National MPS Society is committed to making a difference in the lives of MPS families through support, research, education, and advocacy. Families from around the world gain a better understanding of these rare genetically determined diseases through the Society’s assistance in linking them with healthcare professionals, researchers, and, perhaps most importantly, each other.

Learn more at mpssociety.org

The National Niemann-Pick Disease Foundation, Inc. (NNPDF) is a non-profit, patient advocacy and family support organization dedicated to supporting and empowering patients and families affected by Niemann-Pick disease, through education, collaboration and research. Founded in 1993, NNPDF serves families throughout the nation at all stages of their Niemann-Pick journey.

Learn more at nnpdf.org

The National PKU Alliance (NPKUA) works to improves the lives of individuals with PKU, pursue a cure by expanding research, and provide education and support to individuals living with PKU and their caregivers. Since its inception in 2008, NPKUA has supported numerous successful fundraising events, conferences, and internal support programs and has remained steadfast in its support of research endeavors.

Learn more at npkua.org

Parent Project Muscular Dystrophy (PPMD) is the largest nonprofit organization in the United States focused entirely on Duchenne muscular dystrophy. They take a comprehensive approach in the fight against Duchenne—funding research, raising awareness, promoting advocacy, connecting the community, and broadening treatment options.

Learn more at parentprojectmd.org

The Pompe Alliance is a Public Services Organization dedicated to the ideas of support, empowerment, and progress. It seeks to provide supportive services and information to patients, caregivers, medical professionals, and community stakeholders through a number of initiatives: financial assistance, advocacy, education, mentoring, and research recruitment

Learn more at pompealliance.com

The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis. Until this goal is achieved, the PFF is committed to advancing improved care of patients with PF and providing unequaled support and education resources for patients, caregivers, family members, and health care providers.

Learn more at pulmonaryfibrosis.org

The United Pompe Foundation was formed to assist patients and/or their families with medical costs and other expenses that these patents and families face and may not be able to cover, or fully cover, through their insurance.

Learn more at unitedpompe.com